NADINA trial: neoadjuvant ipilimumab + nivolumab shows superior EFS in resectable stage III melanoma

Minke W. Lucas, MD, Netherlands Cancer Institute, Amsterdam, The Netherlands, discusses the results of the Phase III NADINA trial (NCT04949113), which demonstrated significantly improved event-free survival (EFS) with neoadjuvant ipilimumab plus nivolumab compared to adjuvant nivolumab in resectable stage III melanoma. At 18 months, EFS was 80.8% for the neoadjuvant arm vs 53.9% for the adjuvant arm. Distant metastasis-free survival (DMFS) was also higher, at 85.7% vs 62.4%. Patients with a major pathological response or radiological complete/partial response showed notably high recurrence-free and distant metastasis-free survival rates. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.